OTC:AVAI
AVAI BIO, INC.
A clinical-stage biotech firm targeting rare disease treatments with a focus on advancing its proprietary drug pipeline through strategic financing.
Key Metrics
Investment Thesis
Bull Case
Early-stage biotech investments offer the potential for exponential returns if a key clinical trial succeeds and regulatory approval is granted; The company may have valuable intellectual property assets that could be licensed to larger pharmaceutical firms at a premium; Strategic partnerships or grant funding could provide non-dilutive capital to extend runway without immediate shareholder dilution.
Bear Case
The absence of any revenue stream for the last five years combined with a massive $4.1M deficit makes the stock highly speculative and prone to total loss; Current liabilities exceed assets by over $1.5M, signaling potential insolvency if financing dries up soon; Investors face extreme dilution risk as the company will likely need to issue new shares repeatedly to cover its negative cash flow.
About AVAI BIO, INC.
AVAI BIO, Inc. (AVAI) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare diseases and serious conditions. The company operates primarily in the United States and leverages advanced research methodologies to advance its pipeline from discovery to clinical trials.
Analysis
Management Discussion
The company reported a net loss of $1.1M in 2025 following a larger loss of $2.1M in 2024, driven by substantial operating expenses and general and administrative costs totaling over $1.5M. Cash flow from operations was negative $1.2M while cash flow from financing provided $1.2M, indicating the company is currently dependent on equity or debt issuance to fund its research activities rather than organic growth.
Industry Overview
The rare disease biotechnology sector is characterized by high regulatory hurdles and long development timelines but offers significant market exclusivity opportunities. Companies in this space typically rely heavily on venture capital, government grants, and public markets for funding until achieving product milestones.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $-11.3K | $0 |
| Cost of Revenue | $0 | $-390.7K |
| Gross Profit | $-11.3K | $390.7K |
| Operating Expenses | $2.1M | $1.5M |
| Operating Income | $-2.1M | $-1.1M |
| G&A | $1.4M | $762.5K |
| D&A | $77.0K | $74.3K |
| Depreciation | $1.5K | — |
| Other OpEx | $691.4K | $769.5K |
| Non-Operating Income | $0 | $0 |
| Pre-Tax Income | $-2.1M | $-1.1M |
| Income Tax | $0 | $0 |
| Continuing Ops | $-2.1M | $-1.1M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-2.1M | $-1.1M |
| Minority Interest | $0 | $0 |
| Net to Common | $-2.1M | $-1.1M |
| Metric | 2024 | 2025 |
|---|---|---|
| Current Assets | $116.1K | $93.1K |
| Cash & Equivalents | $281 | $81.1K |
| Prepaid Expenses | — | $12.1K |
| Other Current Assets | $115.8K | $0 |
| Long-Term Assets | $205.9K | $131.6K |
| PP&E (Net) | $1.5K | — |
| Intangibles | $205.9K | $131.6K |
| Other LT Assets | $-1.5K | $0 |
| Total Assets | $322.0K | $224.7K |
| Current Liabilities | $1.8M | $1.8M |
| Accounts Payable | $1.1M | $885.3K |
| Current Debt | — | $112.5K |
| Other Current Liab | $706.8K | $790.8K |
| Long-Term Liabilities | $0 | $0 |
| Total Liabilities | $1.8M | $1.8M |
| Shareholders' Equity | $-1.5M | $-1.6M |
| Paid-In Capital | $1.4M | $2.4M |
| Retained Earnings | $-3.0M | $-4.1M |
| Total L&E | $322.0K | $224.7K |
| Metric | 2024 | 2025 |
|---|---|---|
| Net Income (CFO) | $-2.1M | $-1.1M |
| Non-Cash Adjustments | $77.0K | $74.3K |
| Working Capital Changes | $729.2K | $-92.8K |
| Cash from Operations | $-1.3M | $-1.2M |
| Cash from Investing | $-149.0K | $0 |
| Cash from Financing | $1.4M | $1.2M |
| FX Effect | $0 | $0 |
| Net Change in Cash | $-107.2K | $80.8K |
| Beginning Cash | $107.5K | $281 |
| Ending Cash | $281 | $81.1K |
Frequently Asked Questions
How does AVAI BIO, INC. make money?
The company's financial profile indicates operations centered on pharmaceutical research and development, likely funded by grants, partnerships, or equity issuance given the zero revenue and significant negative cash flow from operations. Key activities include preclinical and clinical stage drug development, intellectual property licensing, and potentially strategic collaborations with academic institutions or biotech partners.
What are the main risks for AVAI?
Complete lack of commercial revenue and reliance on external financing creates a high risk of capital constraints; Significant accumulated retained earnings deficit of $4.1M indicates heavy burn without sustainable profitability; Negative cash flow from operations suggests the current business model cannot yet generate self-sustaining funds; High volatility common in pre-revenue biotech sectors with no guaranteed path to market.
What is AVAI's competitive advantage?
Proprietary intellectual property portfolio protecting unique mechanisms of action for rare disease treatments; Access to specialized scientific talent and research infrastructure in the US biotech sector; Potential strategic partnerships that provide non-dilutive funding and co-development capabilities.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.